Loading...
JOINART INTRA-ARTICULAR SYRINGE HYALURONIC ACID 1.6% 2 ML 3 PIECES SF GROUP
Sold out
5% off
€164,05
€172,00
Unit price
/
Unavailable
Tax included, shipping and discounts calculated at checkout.
SF GROUP FENIX | SKU:
934812862
Notify me when it's back in stock!
Write us your email, you will be notified when this product becomes available again!
JOINART INTRA-ARTICULAR SYRINGE HYALURONIC ACID 1.6% 2 ML 3 PIECES SF GROUP is backordered and will ship as soon as it is back in stock.
Shipping Costs and Times
Shipping Costs and Times
- Order fulfillment within 24 hours and delivery within the following 48/72 hours.
- Shipping cost: always free for orders over €49.90, otherwise it costs €4.99.
Payments
Payments
Payment information is processed securely. We do not store credit card information or have access to your credit card information.
Returns and Refunds
Returns and Refunds
You can return and receive a refund for the item within 30 days. See full policy here.
Do you need help?
Our customer service is here to help you!
- Contact us by phone, email or WhatsApp, from Monday to Friday, from 9:00 to 20:00 .
- For common questions, such as tracking your order or checking its fulfillment status, you can count on our artificial intelligence , available 24/7 .
We are always at your side to offer you fast and effective support!
Description
Description
JOINART INTRA-ARTICULAR SYRINGE HYALURONIC ACID 1.6% 2 ML 3 PIECES SF GROUP
FENI X PHARMA
JOINART
32 mg/2 ml
Hyaluronic acid sodium salt 1.6%
Joinart is a substitute for synovial fluid in joints affected by degenerative or mechanical arthropathy, which causes pain or reduced mobility.
Description
Joinart is a medical device with CE marking compliant with the MDD93/42/EEC directive, containing 16 mg/ml of hyaluronic acid obtained by fermentation from a high molecular weight fraction (> 1500 kDa) and not chemically modified.
Joinart is a transparent, sterile, apyrogenic and viscoelastic solution supplied in a 2 ml syringe. Hyaluronic acid is a natural polysaccharide present in many human tissues, particularly in synovial fluid, and acts in joints both as a lubricant for cartilage and ligaments and as a shock absorber. According to many studies, injections of hyaluronic acid in joints affected by osteoarthritis restore the viscosity and elasticity of the synovial fluid, with a consequent reduction in pain and an improvement in joint mobility.
Joinart acts only at the level of the joint into which it is injected, without exerting any systemic action.
Composition
Main component: sterile hyaluronic acid sodium salt 1.6%. Other components: sodium chloride, sodium phosphate and water for injections.
Packaging
Joinart is supplied in a glass syringe containing 32 mg of hyaluronic acid in 2 ml of buffered saline sodium chloride solution, packaged in a blister.
The contents of the syringe are sterilized by moist heat.
Instructions for use
Remove any joint effusion before injecting Joinart; the same needle should be used for removing the effusion and injecting Joinart. Remove the protective cap from the syringe, taking special care to avoid contact with the opening.
Screw the 18- to 22-gauge needle tightly into the Luer-type locking collar to ensure a leak-proof seal.
Before injection, treat the site with an appropriate antiseptic solution. Inject Joinart using an aseptic technique. Inject only into the joint cavity.
Administration
Joinart must be administered weekly for a total of three weeks or in any case according to the medical prescription.
Warnings
• The contents of the pre-filled syringe are sterile.
The syringe is packaged in a sterile blister.
The surface of the syringe is not sterile.
• Do not use Joinart after the expiry date shown on the package.
• Do not use Joinart if the package or syringe are open or damaged.
• The injection site must be on healthy skin.
• Do not inject vascularly. Do not inject outside the joint cavity, into synovial tissues or capsules.
• Joinart has not been tested in pregnant or breastfeeding women.
• Joinart is disposable and does not need to be resterilized.
• Avoid the concomitant administration of Joinart with other products for intra-articular use in order to prevent any possible interaction.
• Do not administer Joinart in the presence of abundant intra-articular effusion.
• Once the package has been opened, Joinart must be used immediately and disposed of in accordance with current regulations.
• Keep out of reach of children.
• As with any invasive joint treatment, the patient is advised to avoid all strenuous physical activity for the first 2-3 days after the injection.
Contraindications
It should not be administered:
• to patients with known sensitivity to hyaluronic acid and related compounds;
• if you have an infection or skin disease near the injection site;
• if the joint is infected or severely inflamed.
Side effects
Some transient side effects may occur following the injection of Joinart, such as pain, stiffness, sensation of heat, redness or swelling.
These side effects can be alleviated by applying ice to the treated joint. They usually disappear after a short time. If symptoms persist, seek medical attention. As with any invasive joint treatment, septic arthritis may occur if proper precautions are not observed during the injection or the injection site is not aseptic.
Storage and expiry
Joinart must be stored in the original packaging at a temperature between 0 and 25°C, away from direct sunlight and frost. The expiry date is indicated on the package.
Cod.
0000000000001
0000000000002
Description
Joinart is a medical device with CE marking compliant with the MDD93/42/EEC directive, containing 16 mg/ml of hyaluronic acid obtained by fermentation from a high molecular weight fraction (> 1500 kDa) and not chemically modified.
Joinart is a transparent, sterile, apyrogenic and viscoelastic solution supplied in a 2 ml syringe. Hyaluronic acid is a natural polysaccharide present in many human tissues, particularly in synovial fluid, and acts in joints both as a lubricant for cartilage and ligaments and as a shock absorber. According to many studies, injections of hyaluronic acid in joints affected by osteoarthritis restore the viscosity and elasticity of the synovial fluid, with a consequent reduction in pain and an improvement in joint mobility.
Joinart acts only at the level of the joint into which it is injected, without exerting any systemic action.
Composition
Main component: sterile hyaluronic acid sodium salt 1.6%. Other components: sodium chloride, sodium phosphate and water for injections.
Packaging
Joinart is supplied in a glass syringe containing 32 mg of hyaluronic acid in 2 ml of buffered saline sodium chloride solution, packaged in a blister.
The contents of the syringe are sterilized by moist heat.
Instructions for use
Remove any joint effusion before injecting Joinart; the same needle should be used for removing the effusion and injecting Joinart. Remove the protective cap from the syringe, taking special care to avoid contact with the opening.
Screw the 18- to 22-gauge needle tightly into the Luer-type locking collar to ensure a leak-proof seal.
Before injection, treat the site with an appropriate antiseptic solution. Inject Joinart using an aseptic technique. Inject only into the joint cavity.
Administration
Joinart must be administered weekly for a total of three weeks or in any case according to the medical prescription.
Warnings
• The contents of the pre-filled syringe are sterile.
The syringe is packaged in a sterile blister.
The surface of the syringe is not sterile.
• Do not use Joinart after the expiry date shown on the package.
• Do not use Joinart if the package or syringe are open or damaged.
• The injection site must be on healthy skin.
• Do not inject vascularly. Do not inject outside the joint cavity, into synovial tissues or capsules.
• Joinart has not been tested in pregnant or breastfeeding women.
• Joinart is disposable and does not need to be resterilized.
• Avoid the concomitant administration of Joinart with other products for intra-articular use in order to prevent any possible interaction.
• Do not administer Joinart in the presence of abundant intra-articular effusion.
• Once the package has been opened, Joinart must be used immediately and disposed of in accordance with current regulations.
• Keep out of reach of children.
• As with any invasive joint treatment, the patient is advised to avoid all strenuous physical activity for the first 2-3 days after the injection.
Contraindications
It should not be administered:
• to patients with known sensitivity to hyaluronic acid and related compounds;
• if you have an infection or skin disease near the injection site;
• if the joint is infected or severely inflamed.
Side effects
Some transient side effects may occur following the injection of Joinart, such as pain, stiffness, sensation of heat, redness or swelling.
These side effects can be alleviated by applying ice to the treated joint. They usually disappear after a short time. If symptoms persist, seek medical attention. As with any invasive joint treatment, septic arthritis may occur if proper precautions are not observed during the injection or the injection site is not aseptic.
Storage and expiry
Joinart must be stored in the original packaging at a temperature between 0 and 25°C, away from direct sunlight and frost. The expiry date is indicated on the package.
Cod.
0000000000001
0000000000002